Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
1. A method of treating a cancer with activated β-catenin in a subject in need thereof, comprising administering an effective amount of a CBP/catenin inhibitor and an effective amount of an immune checkpoint inhibitor to the subject in need thereof, wherein the CBP/catenin inhibitor is (6S,9aS)-N-benzyl-8-(((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide, and wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.